BioAtla, Inc.
BCAB
$4.54
$0.020.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.00M | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.00M | -- | -- | -- | 0.00 |
| Cost of Revenue | 8.00M | 9.54M | 13.68M | 12.36M | 11.65M |
| Gross Profit | -6.00M | -9.54M | -13.68M | -12.36M | -11.65M |
| SG&A Expenses | 3.26M | 4.25M | 4.96M | 5.26M | 4.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.26M | 13.79M | 18.65M | 17.61M | 16.24M |
| Operating Income | -9.26M | -13.79M | -18.65M | -17.61M | -16.24M |
| Income Before Tax | -9.78M | -15.78M | -18.71M | -15.33M | -14.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.78M | -15.78M | -18.71M | -15.33M | -14.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.78M | -15.78M | -18.71M | -15.33M | -14.88M |
| EBIT | -9.26M | -13.79M | -18.65M | -17.61M | -16.24M |
| EBITDA | -9.24M | -13.73M | -18.53M | -17.43M | -16.02M |
| EPS Basic | -8.18 | -13.43 | -15.99 | -13.16 | -14.99 |
| Normalized Basic EPS | -5.11 | -8.39 | -9.99 | -8.23 | -9.37 |
| EPS Diluted | -8.18 | -13.43 | -15.99 | -13.16 | -14.99 |
| Normalized Diluted EPS | -5.11 | -8.39 | -9.99 | -8.23 | -9.37 |
| Average Basic Shares Outstanding | 1.20M | 1.17M | 1.17M | 1.17M | 993.10K |
| Average Diluted Shares Outstanding | 1.20M | 1.17M | 1.17M | 1.17M | 993.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |